Search

Esophageal squamous cell carcinoma (ESCC) remains one of the leading cause of cancer-related death in China. Moreover, more than 90% of the ESCC patients have been in the advanced stage when diagnosed, the 5-year survival is very poor even though the medical techniques have been improved in the past decades. Although the accumulated evidences have suggested the crucial role of genetic changes in esophageal carcinogenesis, the target therapy based on these genetic changes is largely in the very beginning, and radical esophagectomy and radiochemotherapy remain the chief choice for ESCC treatment at present. The present study was thus designed to evaluate the efficacy of the present treatment methods in China to provide more information for optimal choice in advanced ESCC treatment. The enrolled 20,712 ESCC patients in this study were from the ESCC database in Henan Key Laboratory for Esophageal Cancer Research of the First Affiliated Hospital, Zhengzhou University. Of the patients, there were 12,818 males with a mean age of 59.59±8.2 and 7,894 females with a mean age of 60.34±8.3. All the 20,712 patients were confirmed by histopathology as ESCC at II to IV stage (advanced stage) and classified into three groups based on the treatment methods: radical esophagectomy (R0) alone (17,577, 84.8%), R0 plus radiochemotherapy (2,510, 12.1%) and radiochemotherapy alone (625, 3.1%). The followed-up was undertaken until 2016. The SPSS21.0 software and Kaplan-Meier survival analysis and Log Rank test were used to evaluate the efficiency of different treatments. The results demonstrated that the overall median survival time for the three groups was 5.81 years, 4.82 years and 2.85 years, respectively (P Note: This abstract was not presented at the meeting. Citation Format: Rang Cheng, Fu You Zhou, Neng Chao Wang, Ran Wang, Wei Peng Wang, Xian Zeng Wang, Wen Bin Yue, Jian Wei Zhou, Zhan Hui Miao, Guang Cheng Ding, De Chao Bu, Li Dong Wang. Impact of the different treatments on the survival of advanced esophageal squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3276. doi:10.1158/1538-7445.AM2017-3276

Lymph node (LN) metastasis has been recognized as one of the most important factors for poor prognosis of esophageal cancer (EC). However, the influence of dissected LN number on metastatic detection rate and survival in EC has not been well documented. The present study was undertaken to correlate the total number of dissected LN, metastatic detection rate and survival on 10,382 EC patients. All the patients had been performed surgical treatment and confirmed as esophageal squamous cell carcinoma (ESCC) by histopathological examination. The patients were from Henan, Hebei and Shanxi provinces, the high incidence areas for EC in northern China, including 6,375 males with a mean age of 58±9 and 4,007 females with a mean age of 59±9. Of the patients, 2,714 cases have been followed up by interview at home until July, 2010. Eight EC groups had been classified based on the total number of dissected LN (1-3, 4-5, 6-7, 8-9, 10-11, 12-13, 14-16 and ≥17). The results showed that the positive metastatic detection rate apparently increased with the total extended dissected LN number (P< 0.05) until reaching the level with a total of 17 or more dissected LN. 5-year survival analysis showed that the patients without LN metastasis had a higher survival rate than those with LN metastasis in all seven groups (P0.05). We concluded that the total dissected LN number could affect the survival rate for EC and that a total of 10 to 16 dissected LN should be recommended for EC surgical treatment. (supported by Innovation Scientists and Technicians Troop Construction Projects of Henan Province). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5525. doi:1538-7445.AM2012-5525